source
- Intellia's single-dose CRISPR therapy slashes hereditary angioedema attacks by 87% in Phase 3 trialIntellia Therapeutics reported that its CRISPR-based gene editing drug lonvo-z achieved a dramatic reduction in swelling attacks for patients with hereditary angioedema (HAE) in a Phase 3 study. T…